C ardiovascular diseases (CVDs) are complex and heterogeneous in nature and are caused by multiple genetic, environmental, and behavioral factors. Precision cardiovascular medicine transitions from a one-size-fits-all approach to focusing on the prevention of a single patient's CVD instead. Moreover, it uses tailored preventive, diagnostic, prognostic, and therapeutic strategies based on specifics derived from an individual's genome, clinical features, biomarkers, cardiovascular imaging results, behavioral idiosyncrasies, and environmental factors. The exponential growth of big data analytics in CVD and advances in bioinformatics are revolutionizing cardiovascular clinical care, necessitating the expertise of bioinformatics-literate physicians. To date, the field of oncology has seen advancements with respect to more personalized, target-driven trial designs, because tumor biopsies are easily available to detect genetic mutations. However, precision cardiovascular medicine has only just been introduced; and it has the potential to improve cardiovascular outcomes, quality of patient care, and cost-effectiveness, and reduce hospital admission and mortality rates. This article highlights (1) the insights of precision cardiovascular medicine, (2) the challenges that the next generation of physicians will face, and (3) the way in which the new paradigm might lead to better individualized cardiovascular care.
A TOOLBOX FOR PRECISION CARDIOVASCULAR MEDICINE
The path to adoption of precision cardiovascular medicine requires access to large-scale, well-designed, and standardized electronic health records or precision medicine platforms to connect the omic fields (ie, genomics, metagenomics, metabolomics, and proteomics) with clinical features, biomarkers, human microbiome sequencing, genome editing, cardiovascular imaging, and behavioral factors geared toward individualized cardiovascular care. It is likely that, in the future of cardiovascular medicine, big data analytics and bioinformatics will potentially force us toward more personalized targeted therapy. In brief, precision cardiovascular medicine requires the potential toolbox that can be categorized into (1) big data analytics, (2) data sharing medicine, and (3) deep learning algorithms.
Big Data Analytics
With the continuous exponential growth of big data and continual emergence of scientific technologies, physicians are facing myriads of data, and researchers are under pressure to innovate faster than ever. In fact, the concept of big data is not a new one, and big data analytics has already started to play a pivotal role in the revolution of cardiovascular care, and potential improvements in cardiovascular outcomes and quality of patient care. Big data analytics may initiate novel inves-tigations and could facilitate a paradigm shift to datadriven knowledge.
1 Via the analysis of large amounts of heterogeneous CVD data, big data analytics might reveal novel genotypes and phenotypes that can indicate differential therapies and personalized targeted therapy. Therefore, precision cardiovascular medicine forces big data analytics into the equation for clinical practice to provide the highest quality of patient care.
Data Sharing Medicine
Data sharing has incredible potential to strengthen cardiovascular research, clinical practice, and development of clinical trial designs. For example, The New England Journal of Medicine has creatively initiated The SPRINT Data Analysis Challenge for researchers, data analysts, and physicians. This challenge is aimed to demonstrate that clinical trial data sharing can be used to identify novel clinical findings beyond the results of the SPRINT trial (Systolic Blood Pressure Intervention Trial). In the MyHeart Counts smart phone apps-based study of cardiovascular health, McConnell et al 2 demonstrated that the transcription of individuals' data into code to be stored and shared in the cloud system was feasible. In fact, with the precision medicine platforms such as the Trans-Omics for Precision Medicine program, new sources of big data for physicians and researchers come together for allowance of the performance of analysis. Furthermore, these platforms still remain largely unexplored and thus have the potential to enable data sharing in cardiovascular medicine.
Deep Learning Algorithms
Deep learning mimics the operation of the human brain by using multiple layers of neuronal networks that can generate predictions from input training data sets. Deep learning is a growing field and can be a very powerful tool for image recognition, and may potentially be used in cardiovascular imaging for exploring novel clinical findings and for making automated predictions. 3 In fact, deep learning has potential to improve performance in pattern recognition and image analysis in cardiovascular imaging. Therefore, deep learning could leverage cardiovascular imaging and potentially help to identify novel phenotypes of heterogeneous syndromes.
WHAT DISEASES SHOULD BE TARGETED IN PRECISION CARDIOVASCULAR MEDICINE?
To date, several studies have found that the heterogeneity of CVDs could be categorized into subgenotypes or phenotypes, and could potentially lead to differences in the response to treatment, which may support the development of personalized targeted therapy. Deep learning can be used to classify novel genotypes and phenotypes from heterogeneous CVDs such as heart failure with preserved ejection fraction, hypertension, pulmonary hypertension, acute coronary syndrome, and cardiomyopathy. Shah et al 4 created a machine learning model to identify intrinsic structures in patients with heart failure with preserved ejection fraction, using 46 different variables, and successfully identified 3 distinct groups with clear differences in desired outcomes (eg, mortality and hospitalization). In addition, a recent study suggests that the use of the global coronary heart disease genetic score not only can reduce the number needed to treat for statins, but also targets those who may have increased relative risk reductions with statin therapy. 5 These are excellent examples of how precision medicine may more precisely target individuals with CVD.
CURRENT CHALLENGES IN PRECISION CARDIOVASCULAR MEDICINE
Although precision cardiovascular medicine is at a nascent stage but is a growing field, its potential barriers include concerns regarding cost-effectiveness and data privacy, the necessary development of a standardized electronic health record, the current lack of quality control, genetic causality in genotype-phenotype correlation, the lack of large-scale randomized controlled trials validating drug therapies with genetic information, and training in medical education. In addition, patients with the early stage of CVD might not be good candidates for precision medicine because nonpharmacological therapy is cost-effective and generalizable, in comparison with genetic testing in precision medicine. Nonpharmacological prevention and therapy such as weight loss, salt reduction, diet modification, smoking cessation, vaccination, and stress reduction could benefit patients because it is an absolute risk reduction with no potential side effects and seems to have worked well in terms of return on investment for society (Figure) .
THE FUTURE OF PHYSICIANS IN PRECISION CARDIOVASCULAR MEDICINE
In the future, because current medical professionals appear to be underequipped to take on precision cardiovascular medicine, adequate preparation is needed for the next generation of physicians for precision cardiovascular medicine. The American Medical Informatics Association has launched a clinical informatics fellowship, accredited by the Accreditation Council for Graduate Medical Education, to help physicians better understand bioinformatics, data mining, and big data analytics, and potentially help move the industry toward precision cardiovascular medicine. Moreover, the Icahn School of Medicine at Mount Sinai and Google Life Sciences have collaborated to start an innovative joint fellowship program for postgraduate training in big data research using advanced technologies. Other options for busy physicians include Continuing Medical Education courses and online diplomas or certificates.
Conclusions
Cardiovascular care is shifting to the paradigm known as precision cardiovascular medicine, which incorporates unique biological features, clinical features, omic biomarkers, human microbiome signatures, and cardiovascular imaging into clinical practice. Although there is much promise in being able to include precision cardiovascular medicine in clinical practice, the current reality is that the implementation of precision medicine in cardiovascular care is still in its infancy, but it is growing. In addition, educating physicians about health informatics and implementing genetics/bioinformatics courses in medical education will be important for the next generation of physicians.
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